[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538731":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Arbeitsgemeinschaft medikamentoese Tumortherapie","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Richard Greil, MD","Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Daniela Wolkersdorfer, Dr.","CONTACT","+436626404412","office@agmt.at",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Universitätsklinik für Innere Medizin III, PMU Salzburg","RECRUITING","Salzburg","State of Salzburg","5020","Austria","AT",{"type":29,"coordinates":30},"Point",[31,32],13.04399,47.79941,{"lat":32,"lon":31},[35],{"name":10,"role":12,"phone":7,"phoneExt":7,"email":7},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100538731","agmt-austrian-lymphoma-registry-100538731",false,"NCT06294652","AGMT Austrian Lymphoma Registry","Inclusion Criteria:\n\n* The registry will include patients ≥ 18 years with lymphoma.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria.","ALL","18 Years",{"count":47,"type":48},4000,"ESTIMATED","10 Years","OBSERVATIONAL","Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).\n\nThere are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.\n\nNon-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), myeloma, and other rarer subgroups.\n\nMany of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities.\n\nNovel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis.\n\nLymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus.",[53],"Lymphoma",[53,55],"Diffuse large B-cel lymphoma (DLBCL)","2025-04-09",{"date":58,"type":59},"2025-04-10","ACTUAL",{"date":61,"type":59},"2024-02-27",{"date":63,"type":48},"2033-12-31",{"name":5,"class":6},1]